Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2010 / Cilt: 19 - Sayı: 3

Evaluation of efficacy of plasmapheresis in nephrology practice: A single center experience

Nefroloji pratiğinde plazmaferez etkinliğinin değerlendirilmesi: Tek merkez deneyimi

Pages
202–205
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, plasmapheresis is an effective and reasonable treatment option in Nephrology practice for cases that do not respond to standard immunosuppressive therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Plasmapheresis is a method of cleaning the high molecular weight solutes such as immune complexes, protein-bound toxins, autoantibodies, cryoglobulins, myeloma light chains, and endotoxins from the extracorporeal blood plasma with removal techniques.
📊
Key Findings & Data:In our study, patients treated with plasmapheresis at the GATA Nephrology Department in the last 10 years (2000-2010) were retrospectively analysed to evaluate the efficacy of plasmapheresis. 28 patients treated with plasmapheresis were enrolled in the study.
💡
Conclusion & Impact:In conclusion, plasmapheresis is an effective and reasonable treatment option in Nephrology practice for cases that do not respond to standard immunosuppressive therapy.
🔬Design:Research Article
📍Scope:2000-2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Plasmapheresis is a method of cleaning the high molecular weight solutes such as immune complexes, protein-bound toxins, autoantibodies, cryoglobulins, myeloma light chains, and endotoxins from the extracorporeal blood plasma with removal techniques. Generally supportive therapy with plasmapheresis has been used as a primary treatment option in many nephrological, neurological, and hematologic diseases. In nephrology practice, it is used for disorders such as renal transplantation, anti-GBM disease and rapidly progressive glomerulonephritis. In our study, patients treated with plasmapheresis at the GATA Nephrology Department in the last 10 years (2000-2010) were retrospectively analysed to evaluate the efficacy of plasmapheresis. 28 patients treated with plasmapheresis were enrolled in the study. Of the patients; 9 (32.15%) were postransplant rejection, 7 (25.00%) crescentic glomerulonephritis, 6 (21.43%) antiglomerular basement membrane disease, 2 (7.14%), multiple myeloma, 2 (7.14%) hemolytic uremic syndrome, 1 (3.57%) focal segmental glomerulosclerosis and 1 (3.57%) case of membranoprolipherative glomerulonephritis. Patients were treated with a total of 265 plasmapheresis sessions. We found that patients treated with plasmapheresis benefited from treatment with the removal of macromolecules such as immuncomplexes and immunoglobulins; better prognosis and decreased mortality were achieved. In conclusion, plasmapheresis is an effective and reasonable treatment option in Nephrology practice for cases that do not respond to standard immunosuppressive therapy.

Özet

Plazmaferez immünkompleksler, proteine bağlı toksinler, otoantikorlar, kriyoglobulinler, miyeloma hafif zincir, endotoksinler gibi yüksek molekül ağırlıklı solütlerin plazmadan ekstrakorporeal kan temizleme teknikleri ile uzaklaştırılması yöntemidir. Plazmaferez genellikle destek tedavisi olarak kullanılmakla beraber birçok nefrolojik, nörolojik ve hematolojik hastalıkta primer tedavi seçeneği haline gelmiştir. Nefroloji pratiğinde sıklıkla renal transplantasyon, anti GBM hastalığı ve hızlı ilerleyen glomerülonefrit gibi hastalıklarda kullanılmaktadır. Çalışmamızda GATA Nefroloji Bilim Dalı tarafından son 10 yılda (2000-2010) plazmaferez tedavisi uygulanan hastaların retrospektif olarak incelenmesi ve plazmaferez etkinliğinin değerlendirilmesi amaçlanmıştır. Çalışmaya plazmaferez tedavisi uygulanan 28 hasta alındı. Hastaların 9'u (%32,15) posttransplant rejeksiyon, 7'si (%25,00) kresentik glomerülonefrit, 6'sı (%21,43) antiglomeruler bazal membran hastalığı, 2'si (%7,14) multipl miyelom, 2'si (%7,14) hemolitik üremik sendrom ve 1'er (%3,57) vaka fokal segmental glomerüloskleroz ve membranoproliferatif glomerülonefrit tanısı ile takip edilmekteydi. Hastalara toplam 265 seans plazmaferez tedavisi uygulandı. Plazmaferez uyguladığımız hastalarda hastalıkların patogenezinde rol oynayan immünkomplekslerin, immünglobulinlerin ve makromoleküllerin uzaklaştırılması ile tedaviden yarar gördüklerini, daha iyi prognoz sağlandığını ve mortalitenin azaldığını saptadık. Sonuç olarak plazmaferez nefroloji pratiğinde immünsüpresif tedavi ile yanıt alınamayan vakalarda başvurulan seçkin ve etkili bir tedavi seçeneğidir.

🔖

Cite This Article

KARAMAN, M., VURAL, A., YENİCESU, M., ÇAĞLAR, K., OĞUZ, Y., YILMAZ, M. İ., EYİLETEN, T., AY, S. A., ALTUN, B., ÇAKAR, M. (2022). Evaluation of efficacy of plasmapheresis in nephrology practice: A single center experience. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 19 - Sayı: 3, 202–205. https://ajindex.com/articles/636495

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Madore F, Lazarus JM., Brady HR: Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 1996; 7:367-386 2. Johnson JP, Moore J Jr, Austin HA 3rd, Balow JE, Antonovych TT, Wilson CB: Therapy of anti-glomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 1985; 64:219. 3. Clark WF, Rock GA, Buskard N, Shumak KH, LeBlond P, Anderson D, Sutton DM: Therapeutic plasma exchange: An update from the Canadian Apheresis Group. Ann Intern Med 1999; 131:453 4. Donmez O, Celebi S, Okan M, Dilek K: Atypical hemolytic uremic syndrome: Report of a pediatric case. Turk Neph Dial Transpl 2001;10(3):186-188 5. Polat M, Ceylan BG, Alanoğlu G, Eroğlu F, Sipahi T: Süleyman Demirel Üniversitesi Hastanesi Yoğun Bakım Ünitesi plazmaferez uygulamaları. S.D.Ü. Tip Fak. Derg. 2009;16(4);1-4 6. Smith JW, Weinstein R, AABB Hemapheresis Committee: Therapeutic apheresis: A summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion 2003; 43:820. 7. Szczepiorkowski ZM, Shaz BH, Bandarenko N, Winters JL: The new approach to assignment of ASFA categories--introduction to the fourth special issue: clinical applications of therapeutic apheresis. J Clin Apher 2007; 22:96 8. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Shaz BH, Weinstein R, Wirk A, Winters JL: Evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007; 22:106 9. Evrenkaya TR, Atasoyu EM: Extracorporal techniques in the treatment of mushroom poisoning. Turk Neph Dial Transpl 2001;10(1):14-18 10. Russo GE, Giusti S, Maurici M, Bosco M, Vitalino E, Caramiclo MS, Bauco B, De Marco CM, Marigliano V: Plasmapheresis and mushroom poisoning: Report of a case of Amanita phalloides poisoning. Clin Ter 1997;148:277-280 11. Chaiear K, Limpaiboon R, Mecchai C, Poovorawan Y:Fatal mushroom poisoning caused by Amanita virosa in Thailand. Southeast Asian J Trop Med Public Health 1999; 30: 157-160 12. Demirkan F, Öztop İ: Nörolojik Hastalıklarda Plazmaferez, Damla Kan Merkezleri ve Transfüzyon Derneği Bülteni. 1998; 19: 6-7 13. Eşkazan E: Aferez Komplikasyonları. İ.Ü.Cerrahpaþa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri Herkes İçin Transfüzyon Tıbbi Sempozyum Dizisi. 2005; 44: 203-218 14. Mokrzycki MH, Kaplan AA: Therapeutic plasma exchange: Complications and management. Am